Trial Information

Summary: Cystic Fibrosis Study CTBM100C2302

Novartis Pharmaceuticals Corporation and Chiron Corporation are conducting a clinical research study to compare the safety and effectiveness of an investigational formulation, Tobramycin Inhalation Powder (TIP), compared to Tobramycin Inhalation Solution (TOBI®) for participants 6 years of age and older, that have Cystic Fibrosis and a lung infection caused by the bacteria Pseudomonas aeruginosa. The purpose of this clinical research study is to study how breathing in TIP twice a day compares to breathing in TOBI®. Tobramycin Inhalation Powder (TIP) is an "investigational formulation", which means that it is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA). TOBI® is a drug that has been approved for sale in the United States by the U.S. Food and Drug Administration (FDA) for the treatment of Pseudomonas aeruginosa infections in Cystic Fibrosis patients.

Participants will be required visit the study center approximately 12 times over a 25 week period.
For more information about this clinical trial, visit www.NovartisClinicalTrials.com

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: August 15, 2008 at 1:35:30 PM